Jonathan Slonin Sells 879 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) insider Jonathan Slonin sold 879 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $18.40, for a total value of $16,173.60. Following the sale, the insider now owns 93,444 shares in the company, valued at approximately $1,719,369.60. The trade was a 0.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Pacira BioSciences Trading Up 1.3 %

PCRX traded up $0.23 during trading on Monday, hitting $18.63. 581,938 shares of the company’s stock were exchanged, compared to its average volume of 547,046. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $35.95. The stock has a 50 day moving average price of $18.06 and a 200 day moving average price of $17.92. The firm has a market cap of $860.20 million, a P/E ratio of -9.18 and a beta of 0.76. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Institutional Trading of Pacira BioSciences

Several large investors have recently added to or reduced their stakes in PCRX. Pacer Advisors Inc. lifted its position in Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after acquiring an additional 2,799,434 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Pacira BioSciences by 314.4% in the third quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock valued at $8,324,000 after purchasing an additional 419,656 shares during the period. Doma Perpetual Capital Management LLC grew its holdings in Pacira BioSciences by 71.8% during the 2nd quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock valued at $28,632,000 after purchasing an additional 418,321 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after buying an additional 288,662 shares during the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of Pacira BioSciences during the third quarter worth about $3,469,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Jefferies Financial Group upped their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Barclays dropped their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Royal Bank of Canada increased their target price on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.50.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.